A three-part, double-blind, placebo-controlled, Phase I/Ib study of the safety, tolerability and pharmacokinetics of single and multiple ascending doses of IMU-856 in healthy volunteers and patients with celiac disease.

  • Brown, Gregor (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date20/09/22 → 1/06/24

Keywords

  • Clinical trial
  • IMU-856